IMCIVREE

This brand name is authorized in Estonia, Spain, France, Croatia, Ireland, Israel, Italy, Lithuania, Poland

Active ingredients

The drug IMCIVREE contains one active pharmaceutical ingredient (API):

1 Setmelanotide UNII N7T15V1FUY - SETMELANOTIDE

Setmelanotide is a selective MC4 receptor agonist. MC4 receptors in the brain are involved in regulation of hunger, satiety, and energy expenditure. In genetic forms of obesity associated with insufficient activation of the MC4 receptor, setmelanotide is believed to re-establish MC4 receptor pathway activity to reduce hunger and promote weight loss through decreased caloric intake and increased energy expenditure. Read about Setmelanotide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
IMCIVREE Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A08AA12		A Alimentary tract and metabolism → A08 Antiobesity preparations, excl. diet products → A08A Antiobesity preparations, excl. diet products → A08AA Centrally acting antiobesity products
Discover more medicines within A08AA12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1857539
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1211564001
Country: FR	Base de données publique des médicaments	Identifier(s): 69966525
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9018
Country: IT	Agenzia del Farmaco	Identifier(s): 049605013, 049605025
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1092974
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100464076